Abstract
Complications during follow-up - including loss of seal and graft migration with endoleakage - are the Achilles heel of endovascular abdominal and thoracic aneurysm repair (EVAR and TEVAR, respectively). At the level of the proximal and distal landing zones, the characteristics of aortic anatomy include length and shape, thrombus, calcification, kinking and progressive dilatation, and these may ...
Abstract
Complications during follow-up - including loss of seal and graft migration with endoleakage - are the Achilles heel of endovascular abdominal and thoracic aneurysm repair (EVAR and TEVAR, respectively). At the level of the proximal and distal landing zones, the characteristics of aortic anatomy include length and shape, thrombus, calcification, kinking and progressive dilatation, and these may impact the long-term durability of endovascular repair. Endoanchors have been shown to mimic the stability of a hand sewn aortic anastomosis. This report gives an overview of current literature on the use of endoanchors in EVAR and TEVAR. Indications for use include primary implantation to secure the proximal or distal landing zone, in case of unfavourable anatomy or intraoperative type I endoleak/suboptimal apposition to the aortic wall, as well as secondary use for the treatment of type I endoleaks and stent-graft migration often in conjunction with a proximal or distal extension of the stent-graft. To conclude the report, we analysed perioperative results of the first 100 patients treated with TEVAR/EVAR and endoanchors - primarily or secondarily - during re-interventions in our department. From March 2011 to November 2015, 100 patients (85 men, 15 women; mean age 70 +/- 9.7 years) were treated. 82 applications were carried out in the abdominal and 18 in the thoracic aorta. The implantation was performed during the primary EVAR/TEVAR procedure in 80 cases (group A); 20 patients were treated secondarily (group B). Technical success was 100%. Clinical success was 98%. No endoanchors were lost. Perioperative mortality was 4% and morbidity 7%. During 30-day follow-up, endoleaks were found in 8/96 surviving patients. 7/8 patients had type II endoleaks, and one patient with secondary proximal extension of the thoracic stent-graft had a persistent type I endoleak.
Altmetric